Skip to Content Skip to Search

Investors

Latest results

From quarterly updates to key announcements, here you can access all GSK investor-related information.

Scroll to explore

We’re confident in our future

Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery over the next five years.

Latest announcements and results

Emma Walmsley in a blue dress

2022 Second quarter results announcement

Quarterly results
27 July 2022

We announced our second quarter results for the period which ended 30 June 2022 on Wednesday 27 July.

DNA science image

GSK publishes Prospectus and Circular

Press release

We have published the Prospectus and Circular for the proposed demerger of our Consumer Healthcare business to form Haleon.

 

Immuno oncology science image

Completion of the demerger of Haleon and share consolidation of GSK

Press release
18 July 2022

GSK plc has today completed the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. 

Shingles cell

Completion of GSK Share Consolidation

Press release
18 July 2022

GSK plc is pleased to announce that further to the Circular and Notice of General Meeting published by GSK on 1 June 2022, and following the announcements of 6 July 2022 that shareholder approval was granted at the GSK General Meeting and of 18 July 2022 that GSK has completed the demerger of the Consumer Healthcare business from the GSK Group to form Haleon.

Key dates

27
July

Quarterly results

We will announce our second quarter 2022 results on Wednesday 27 July. A live webcast of the event will be available at 12:00 BST / 07:00 EDT.

Register to webcast
16
Sep

Industry conferences

Emma Walmsley, CEO, will present at the BofA Global Healthcare Conference on Friday 16 September.

02
Nov

Quarterly results

We will announce our third quarter 2022 results on Wednesday 2 November. A live webcast of the event will be available at 12:00 GMT / 07:00 EST.

two scientists talking

Get in touch with our investor team

Back to top